DAIC

MARCH 28, 2024

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

TAVR 111

TAVR Stenosis Aortic Aortic valve 111

DAIC

JUNE 7, 2024

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves.

TAVR 111

TAVR Aortic valve Aortic Stenosis 111

DAIC

APRIL 9, 2024

The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East.

TAVR 59

TAVR Aortic valve Aortic Anatomy 59

DAIC

MARCH 25, 2024

24, which will be held April 6-8, 2024, at Atlanta at the Georgia World Congress Center. Bishop Keynote by Gerald Blackwell, MD, MBA, FAAC 2024 Keynote Presentations “We know what the growing complexity of coordinating care, multifaceted care and the need to really get the science up to the forefront.

Education 59

Education Cardiogenic Shock Heart Failure Plaque 59